Last reviewed · How we verify

S-1 [Tegafur/Oteracil/gimeracil]

AstraZeneca · Phase 3 active Small molecule

S-1 [Tegafur/Oteracil/gimeracil] is a Antineoplastic agent Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Advanced gastric cancer, Pancreatic cancer.

S-1 works by inhibiting thymidylate synthase, which is necessary for DNA synthesis, thereby inducing apoptosis in cancer cells.

S-1 works by inhibiting thymidylate synthase, which is necessary for DNA synthesis, thereby inducing apoptosis in cancer cells. Used for Advanced gastric cancer, Pancreatic cancer.

At a glance

Generic nameS-1 [Tegafur/Oteracil/gimeracil]
SponsorAstraZeneca
Drug classAntineoplastic agent
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

S-1 is a combination of tegafur, a prodrug of 5-fluorouracil, oteracil, which inhibits the degradation of 5-fluorouracil, and gimeracil, which enhances the concentration of 5-fluorouracil. This combination allows for a higher dose of 5-fluorouracil to be administered, while minimizing gastrointestinal toxicity.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about S-1 [Tegafur/Oteracil/gimeracil]

What is S-1 [Tegafur/Oteracil/gimeracil]?

S-1 [Tegafur/Oteracil/gimeracil] is a Antineoplastic agent drug developed by AstraZeneca, indicated for Advanced gastric cancer, Pancreatic cancer.

How does S-1 [Tegafur/Oteracil/gimeracil] work?

S-1 works by inhibiting thymidylate synthase, which is necessary for DNA synthesis, thereby inducing apoptosis in cancer cells.

What is S-1 [Tegafur/Oteracil/gimeracil] used for?

S-1 [Tegafur/Oteracil/gimeracil] is indicated for Advanced gastric cancer, Pancreatic cancer.

Who makes S-1 [Tegafur/Oteracil/gimeracil]?

S-1 [Tegafur/Oteracil/gimeracil] is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is S-1 [Tegafur/Oteracil/gimeracil] in?

S-1 [Tegafur/Oteracil/gimeracil] belongs to the Antineoplastic agent class. See all Antineoplastic agent drugs at /class/antineoplastic-agent.

What development phase is S-1 [Tegafur/Oteracil/gimeracil] in?

S-1 [Tegafur/Oteracil/gimeracil] is in Phase 3.

What are the side effects of S-1 [Tegafur/Oteracil/gimeracil]?

Common side effects of S-1 [Tegafur/Oteracil/gimeracil] include Diarrhea, Nausea, Vomiting, Fatigue, Anemia.

What does S-1 [Tegafur/Oteracil/gimeracil] target?

S-1 [Tegafur/Oteracil/gimeracil] targets Thymidylate synthase and is a Antineoplastic agent.

Related